CM Hospitalar S/A Future Growth

Future criteria checks 0/6

CM Hospitalar S/A is forecast to grow earnings and revenue by 125.4% and 6% per annum respectively. EPS is expected to grow by 112.2% per annum. Return on equity is forecast to be 0.3% in 3 years.

Key information

125.4%

Earnings growth rate

112.18%

EPS growth rate

Healthcare earnings growth	30.9%
Revenue growth rate	6.0%
Future return on equity	0.27%
Analyst coverage	Good
Last updated	14 May 2025

Recent future growth updates

Recent updates

CM Hospitalar S/A (BVMF:VVEO3) Looks Inexpensive After Falling 32% But Perhaps Not Attractive Enough

Jun 25

CM Hospitalar S/A (BVMF:VVEO3) Not Doing Enough For Some Investors As Its Shares Slump 49%

May 11

CM Hospitalar S/A (BVMF:VVEO3) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 01

Analysts Are Updating Their CM Hospitalar S/A (BVMF:VVEO3) Estimates After Its Annual Results

Mar 29

Why Investors Shouldn't Be Surprised By CM Hospitalar S/A's (BVMF:VVEO3) 28% Share Price Plunge

Mar 27

Here's Why CM Hospitalar S/A (BVMF:VVEO3) Has A Meaningful Debt Burden

Jan 15

Here's What To Make Of CM Hospitalar S/A's (BVMF:VVEO3) Decelerating Rates Of Return

Dec 14

CM Hospitalar S/A (BVMF:VVEO3) Has More To Do To Multiply In Value Going Forward

Jun 07

Returns On Capital Signal Tricky Times Ahead For CM Hospitalar S/A (BVMF:VVEO3)

Jan 16

Be Wary Of CM Hospitalar S/A (BVMF:VVEO3) And Its Returns On Capital

Aug 31

Statutory Earnings May Not Be The Best Way To Understand CM Hospitalar S/A's (BVMF:VVEO3) True Position

May 17

Pinning Down CM Hospitalar S/A's (BVMF:VVEO3) P/E Is Difficult Right Now

Dec 09

Earnings and Revenue Growth Forecasts

BOVESPA:VVEO3 - Analysts future estimates and past financials data (BRL Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	13,582	-63	839	284	3
12/31/2026	12,835	-3	459	560	7
12/31/2025	12,032	-164	864	297	2
3/31/2025	11,416	-1,477	-84	108	N/A
12/31/2024	11,583	-1,415	-151	34	N/A
9/30/2024	11,570	-61	-175	69	N/A
6/30/2024	11,462	183	-544	-273	N/A
3/31/2024	11,242	326	-662	-372	N/A
12/31/2023	11,084	360	-1,198	-896	N/A
9/30/2023	10,805	162	-142	170	N/A
6/30/2023	10,234	209	-122	173	N/A
3/31/2023	9,647	200	-222	52	N/A
12/31/2022	8,747	260	273	533	N/A
9/30/2022	7,741	278	140	329	N/A
6/30/2022	6,963	286	-17	136	N/A
3/31/2022	6,634	458	79	213	N/A
12/31/2021	6,219	395	194	320	N/A
9/30/2021	6,031	372	102	189	N/A
6/30/2021	5,746	337	N/A	N/A	N/A
3/31/2021	5,055	136	88	158	N/A
12/31/2020	4,413	122	132	186	N/A
12/31/2019	3,003	36	137	163	N/A
12/31/2018	2,641	34	N/A	86	N/A
12/31/2017	1,696	59	N/A	54	N/A
12/31/2016	1,148	165	N/A	59	N/A
12/31/2015	998	-1	N/A	-27	N/A
12/31/2014	866	3	N/A	-82	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VVEO3 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VVEO3 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VVEO3 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VVEO3's revenue (6% per year) is forecast to grow slower than the BR market (6.7% per year).

High Growth Revenue: VVEO3's revenue (6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: VVEO3's Return on Equity is forecast to be low in 3 years time (0.3%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/20 23:38
End of Day Share Price	2025/05/20 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CM Hospitalar S/A is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Gustavo Tiseo	BofA Global Research
Marcio Osako	Bradesco S.A. Corretora de Títulos e Valores Mobiliários
Samuel Campos Alves	BTG Pactual

CM Hospitalar S/A Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 94%

Price target decreased by 9.1% to R$4.57

Price target decreased by 9.9% to R$5.02

Price target increased by 8.9% to R$6.31

Price target decreased by 26% to R$6.01

Price target increased by 10% to R$8.63

Recent updates

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Consensus EPS estimates fall by 94%

CM Hospitalar S/A, Annual General Meeting, Apr 30, 2025

Price target decreased by 9.1% to R$4.57

Returns On Capital At CM Hospitalar S/A (BVMF:VVEO3) Paint A Concerning Picture

Price target decreased by 9.9% to R$5.02

Price target increased by 8.9% to R$6.31

CM Hospitalar S/A (BVMF:VVEO3) Has No Shortage Of Debt

CM Hospitalar S/A to Report Q4, 2024 Results on Mar 20, 2025

New minor risk - Market cap size

Price target decreased by 26% to R$6.01

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target increased by 10% to R$8.63

There Is A Reason CM Hospitalar S/A's (BVMF:VVEO3) Price Is Undemanding

Consensus EPS estimates fall by 23%

Investor sentiment improves as stock rises 16%

Consensus EPS estimates fall by 418%

Price target decreased by 12% to R$8.77

Investor sentiment deteriorates as stock falls 23%

Second quarter 2024 earnings: EPS misses analyst expectations

Now 21% undervalued after recent price drop

Capital Allocation Trends At CM Hospitalar S/A (BVMF:VVEO3) Aren't Ideal

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 19%

CM Hospitalar S/A (BVMF:VVEO3) Looks Inexpensive After Falling 32% But Perhaps Not Attractive Enough

Consensus EPS estimates fall from profit to R$0.0073 loss

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 25%

Price target decreased by 28% to R$11.01

Now 28% undervalued after recent price drop

New major risk - Revenue and earnings growth

CM Hospitalar S/A (BVMF:VVEO3) Not Doing Enough For Some Investors As Its Shares Slump 49%

First quarter 2024 earnings released: EPS: R$0.01 (vs R$0.13 in 1Q 2023)

Price target decreased by 7.1% to R$15.33

Consensus EPS estimates fall by 11%

CM Hospitalar S/A (BVMF:VVEO3) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Analysts Are Updating Their CM Hospitalar S/A (BVMF:VVEO3) Estimates After Its Annual Results

New major risk - Share price stability

Why Investors Shouldn't Be Surprised By CM Hospitalar S/A's (BVMF:VVEO3) 28% Share Price Plunge

Full year 2023 earnings released: EPS: R$1.20 (vs R$0.92 in FY 2022)

Consensus EPS estimates fall by 10%

Price target decreased by 9.5% to R$22.11

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

Price target decreased by 8.4% to R$23.89

Here's Why CM Hospitalar S/A (BVMF:VVEO3) Has A Meaningful Debt Burden

Here's What To Make Of CM Hospitalar S/A's (BVMF:VVEO3) Decelerating Rates Of Return

Price target decreased by 7.7% to R$25.61

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: R$0.021 (vs R$0.19 in 3Q 2022)

Consensus EPS estimates fall by 10%

Second quarter 2023 earnings: Revenues miss analyst expectations

Price target increased by 7.0% to R$26.26

Consensus EPS estimates fall by 14%

CM Hospitalar S/A (BVMF:VVEO3) Has More To Do To Multiply In Value Going Forward

First quarter 2023 earnings released: EPS: R$0.13 (vs R$0.34 in 1Q 2022)

Consensus EPS estimates fall by 13%

Full year 2022 earnings released

Returns On Capital Signal Tricky Times Ahead For CM Hospitalar S/A (BVMF:VVEO3)

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Third quarter 2022 earnings released

Third quarter 2022 earnings released

Investor sentiment deteriorated over the past week

Be Wary Of CM Hospitalar S/A (BVMF:VVEO3) And Its Returns On Capital

CM Hospitalar S/A (BOVESPA:VVEO3) agreed to acquire Neve Industria e Comercio de Produtos Cirurgicos and Nutrifica Comercio de Nutricao Enteral e Parenteral for BRL 110 million.

Second quarter 2022 earnings: EPS misses analyst expectations

Statutory Earnings May Not Be The Best Way To Understand CM Hospitalar S/A's (BVMF:VVEO3) True Position